Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07414992 · ClinicalTrials.gov registry record · Phase 2

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

Not yet
Registry status
Phase 2
Development phase
44
Enrollment target

NCT07414992: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT07414992 is a Phase 2 study that has not yet begun recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07414992, a Phase 2 study, has not yet begun recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
44 participants
Enrollment target

Study Summary

The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for people with muscle-invasive bladder cancer (MIBC).

Interventions

  • DRUG Cemiplimab
  • RADIATION Stereotactic body radiotherapy
  • PROCEDURE Radical cystectomy
  • DRUG Cemiplimab and Fianlimab

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2026-07
Est. Completion 2028-03
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What is known before NCT07414992 opens enrollment

NCT07414992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 4 interventions - of which Cemiplimab is the first listed.

NCT07414992 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07414992 about?

NCT07414992 is a clinical study titled "A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer". The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for people with muscle-invasive bladder cancer (MIBC).

What is the current status of trial NCT07414992?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2026-07. Estimated completion is 2028-03.

What interventions are being tested in trial NCT07414992?

The interventions under investigation include: Cemiplimab (DRUG), Stereotactic body radiotherapy (RADIATION), Radical cystectomy (PROCEDURE), Cemiplimab and Fianlimab (DRUG).

Who is sponsoring clinical trial NCT07414992?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07414992's enrollment target sits among peer trials

44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07414992, the US trial registry maintained by the National Library of Medicine. NCT07414992 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.